Mounjaro Market Review (July 2025 Snapshot)

By Dr Mark Larkin, PhD (Cantab), Medical Director, Pharmacy Price Hound

Introduction

Mounjaro (tirzepatide), Eli Lilly’s dual GIP/GLP-1 receptor agonist, remains one of the most in-demand medicines for type 2 diabetes and weight management in the UK. By July 2025, private prescription pricing had stabilised after months of volatility, with most doses falling between £230–£300 per pack.

This review breaks down the UK pricing by dose, explains why costs vary, and highlights what patients need to know when considering treatment.

July 2025 Price Snapshot

Key trend: Higher doses cost slightly more, but the overall range remains clustered around £250–£300. Patients face relatively small differences per escalation, but the long-term cost is substantial.

Market Trends & Analysis

• Stable but expensive: Unlike newer launches, Mounjaro pricing has stabilised — but at a high baseline.
• Dose-driven costs: Each titration step adds £20–£30, a modest increase, but cumulative costs make monthly treatment financially demanding.
• Comparison with semaglutide: Wegovy (semaglutide) remains cheaper, with starter packs often under £200. This puts price pressure on Mounjaro.
• NHS vs private: Access on the NHS is extremely limited, meaning most patients rely on private prescriptions and absorb the full cost. 

Dr Mark Larkin, PhD

“By July 2025, the Mounjaro market had reached a point of stability. The problem is that stability came at a very high price point. For most patients, £250–£300 per month is unsustainable, and this remains the biggest barrier to wider uptake.” – Dr Mark Larkin, PhD

Shopper Guidance

• Check per-pen cost: Some pharmacies list per-pack prices that mask higher per-injection costs.
• Start low, titrate slowly: Always begin with the starter dose, even if previously on another GLP-1.
• Shop around: Differences of £20–£40 per pack can add up significantly over time.
• Verify regulation: Only purchase from GPhC-registered pharmacies. 

FAQs

Is Mounjaro cheaper than semaglutide?
No. Semaglutide (Wegovy) is generally £40–£60 cheaper per month.

Can I access Mounjaro on the NHS?
Only in highly restricted specialist clinics. For most patients, it remains private only.

Why do prices differ by dose?
Manufacturers and pharmacies set incremental pricing by dose, but much of the cost reflects brand exclusivity rather than production expense.

Will prices fall once generics arrive?
Yes, but generics are unlikely before the late 2020s.

Conclusion

In July 2025, the UK Mounjaro market stabilised, with pricing clustered between £239 and £299 across doses. While the volatility of early 2025 had eased, affordability remained the central issue.

For patients, the decision is less about whether the medicine works, clinical evidence is strong, and more about whether they can sustain the cost long term. Until NHS access expands or generics arrive, Mounjaro will remain a highly effective but financially challenging option.

Disclaimer

This article is for informational purposes only. It does not constitute medical advice. Patients should always consult a licensed prescriber before starting, stopping, or switching medication.

Author & Sources

Author: Dr Mark Larkin, PhD